Cyclotron

AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer’s Disease

Retrieved on: 
Lundi, septembre 26, 2022
Tauopathy, Life Healthcare Group, Precision medicine, Janssen Pharmaceuticals, Laboratory, Cyclotron, Molecular imaging, RU, Brain, Hoffmann-La Roche, Neurodegeneration, CBD, Company, Corticobasal syndrome, Acquisition, SG, GB, Patient, PET, CBS, LMI, AC, CEO, Quality of life, CH, AAIC, Diagnosis, NASDAQ, Dementia, Research, AU, GLOBE, Genentech, Eli Lilly and Company, HIV disease progression rates, NO, PSP, Medical imaging, Virtual, EU

LAUSANNE, Switzerland, Sept. 26, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its partner, Life Molecular Imaging (LMI), is moving PI-2620, the Tau positron-emission tomography (PET) tracer, into late-stage clinical development in Alzheimers disease (AD).

Key Points: 
  • LAUSANNE, Switzerland, Sept. 26, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its partner, Life Molecular Imaging (LMI), is moving PI-2620, the Tau positron-emission tomography (PET) tracer, into late-stage clinical development in Alzheimers disease (AD).
  • As part of the agreement with AC Immune, LMI will make a milestone payment.
  • PI-2620 is a potentially best-in-class Tau PET tracer with high binding affinity and selectivity for aggregated Tau.
  • We are looking forward to continuing the development of PI-2620 as the potentially best-in-class Tau PET tracer in patients with AD.

Radiopharmaceuticals Global Market Report 2022: Radiopharmaceuticals Become Promising for Cancer Theranostics - ResearchAndMarkets.com

Retrieved on: 
Lundi, août 22, 2022
Health, Pharmaceutical, COVID-19, PET, Cancer, Electron, Radionuclide, Degenerative disease, Tissue, Common beta emitters, FDG, Prognosis, Graphite-moderated reactor, Immunology, Prevalence, CAGR, PET/CT, Cardiology, Drug development, Cyclotron, Medical imaging, Pet, Radiopharmaceutical

The "Radiopharmaceuticals - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Radiopharmaceuticals - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Growth in the global market is supported by growing number of nuclear procedures driven by rise in prevalence of cancer, and heart diseases.
  • Significant therapeutic usage of radiopharmaceuticals became possible after the availability of cyclotrons and nuclear reactors which could synthesize large quantities of radioisotopes.
  • The market is further supported by the recent discovery of newer and successful therapeutic applications of radiopharmaceuticals in oncology and cardiology prognosis.

Particle Therapy Market - Global Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
Mardi, juillet 19, 2022
Health, Other Health, Proton, Research, Cancer, Hospital, CAGR, Proton therapy, LLC, Particle, Synchrotron, Cyclotron, USD, Radiation, Government, Hitachi, Medical imaging, Healthcare, EU

The particle therapy market is projected to reach USD 1,004 million by 2027 from USD 677 million in 2022, growing at a CAGR of 8.2% from 2022 to 2027.

Key Points: 
  • The particle therapy market is projected to reach USD 1,004 million by 2027 from USD 677 million in 2022, growing at a CAGR of 8.2% from 2022 to 2027.
  • Market growth is driven by factors such as the various advantages offered by the growing global prevalence of cancer, particle therapy advantages over photon therapy, increasing acceptance of particle therapy in clinical trials, and the increasing number of particle therapy centers worldwide.
  • In 2021, the treatment applications segment is projected to account for the dominant share of 94.4% of the particle therapy market.
  • On the basis of type, the particle therapy market is segmented into proton therapy and heavy ion therapy.

Cyclotron, Inc. Reports Substantial YoY Growth in Revenue, Notching A Win for Its Phenomenal Security Services

Retrieved on: 
Mercredi, juin 22, 2022
Solution, Industry, Intelligence, Technology, Achievement, Growth, Business, Globe, Consultant, Yoy, Microsoft, Enterprise, SAN, Organization, Risk management, Cyclotron

SAN FRANCISCO, June 22, 2022 /PRNewswire-PRWeb/ -- With technological security being the bedrock of successful businesses across the globe, Cyclotron, inc. – the world's leading modern-technology consultants and a top Microsoft security partner to renowned companies worldwide – has reached a new milestone within its security business; registering 300% growth over last 12 months, revenue growth of 210% YoY in Quarter 1, and is on-track for 110% growth YoY for the year 2022.

Key Points: 
  • Known for their robust security services, Cyclotron, inc. has designed services to improve the agility, flexibility and cost effectiveness of the next generation needs of information security and ever-evolving compliance programs.
  • For more details see Cyclotron Security offerings .
  • We offer strategic security guidance and solutions to organizations across the globe, reflecting the market demand for expert guidance to navigate today's complex enterprise security landscape."
  • Moreover, we've placed a strong focus on Enterprise Security Strategy and M&A activities for companies, which has indeed produced exceptional results."

Healthcare Is Personal: GE Healthcare’s Total Molecular Imaging Solutions Enable Precision Health & Theranostics for Personalized Prostate Cancer Care

Retrieved on: 
Jeudi, juin 9, 2022
FDA, Other Health, Technology, Radiology, Pharmaceutical, Oncology, Hospitals, Men, Other Technology, Biotechnology, Science, Alternative Medicine, Other Science, Consumer, Research, Health, Molecule, Radioligand, SNMMI, Time, University of Michigan, CZT, College of Arts and Sciences, Associate, SNR, Organic, Sale, CT, Technology, NYSE, COVID-19, Research, Molecular imaging, Radiopharmaceutical, Nuclear medicine, Cyclotron, News, CEO, CE, Ecosystem, Solution, Artificial intelligence, Federal Food, Drug, and Cosmetic Act, Health, Thomas Edison, Diagnosis, PET/CT, Industry, Radiation, Collection, WEHR, Patient, GE Healthcare, PET/MR, World Health Organization, Noise, Prostate cancer, PET-CT, Radionuclide, University, Physician, Efficiency, Discovery, NEMA, SPECT, PET, Prostate Cancer Foundation, PSMA, Man, LinkedIn, Disease, FDA, FOV, Biology, Risk, Society of Nuclear Medicine and Molecular Imaging, Twitter, CT scan, Medical imaging, Pharmaceutical industry, Medical device, Palladium, Cancer, Radiology, Gallium, Facebook

GE Healthcare is proud to provide cutting-edge molecular imaging solutions that enable and increase access to precision health and theranostics to help improve patient outcomes across care areas, including prostate cancer the most prevalent cancer in men and the third most prevalent cancer overalli.

Key Points: 
  • GE Healthcare is proud to provide cutting-edge molecular imaging solutions that enable and increase access to precision health and theranostics to help improve patient outcomes across care areas, including prostate cancer the most prevalent cancer in men and the third most prevalent cancer overalli.
  • Healthcare is timely and personal and its delivery should be too, explains Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE Healthcare.
  • To prepare for the creation of dedicated theranostics centers, SNMMI and related international molecular imaging societies recently published a new guide for healthcare systems globallyiii.
  • As the industry prepares to usher in this new era of precision health and personalized medicine, GE Healthcare is proud to offer innovative molecular imaging solutions to healthcare systems around the world.

Telix Radiopharmaceutical Production Facility Buildout Commences

Retrieved on: 
Lundi, mars 21, 2022
Company, LinkedIn, TGA, BNP Paribas, Degenerative disease, University, Day of the Walloon Region, Bank account, Prostate, Hospital, Environment, Food, TLX, 2006 Giro d'Italia, Stage 1 to Stage 11, Waste management, ASX, Australian Securities Exchange, Safety, IMBC, MTR, Cyclotron, Regulation of tobacco by the U.S. Food and Drug Administration, GLOBE, Seneffe, FDA, Gallium, Fine chemical, Pharmaceutical industry, Telix, Brussels South

MELBOURNE, Australia and BRUSSELS, Belgium, March 22, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to provide a material update on the development of its radiopharmaceutical production facility in Brussels South (Seneffe) in the Wallonia region of Belgium.

Key Points: 
  • MELBOURNE, Australia and BRUSSELS, Belgium, March 22, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to provide a material update on the development of its radiopharmaceutical production facility in Brussels South (Seneffe) in the Wallonia region of Belgium.
  • It will also be an integral hub for Telixs R&D activities, specifically in relation to the scale-up of radioisotope production.
  • Telix will also contribute 2 million from existing cash reserves for Stage 1, which is projected for completion in 1H 2023.
  • Dr Christian Behrenbruch, Group CEO and Managing Director of Telix said, This manufacturing and R&D facility, and our vertically integrated operations, will further differentiate Telix as a global leader in the radiopharmaceutical industry.

TeamBest Global Companies & Best Cyclotron Systems, Inc. Announce Shipment of World’s Very First 6 MeV Proton Cyclotron

Retrieved on: 
Mercredi, janvier 26, 2022
General Health, Radiology, Hardware, Medical Devices, Technology, Hospitals, Semiconductor, Other Manufacturing, Engineering, Biotechnology, Manufacturing, Health, Proton, Best, Research, Isotope, Cyclotron, Galveston National Laboratory, BCS, TBG, Oil

TeamBest Global Companies (TBG) and Best Cyclotron Systems, Inc. (BCS) announce the shipment of the worlds very first 6 MeV Proton Cyclotron, operating in excess of 500 micro amp current, to a National Lab today.

Key Points: 
  • TeamBest Global Companies (TBG) and Best Cyclotron Systems, Inc. (BCS) announce the shipment of the worlds very first 6 MeV Proton Cyclotron, operating in excess of 500 micro amp current, to a National Lab today.
  • The design, development and manufacture was a combined effort of BCS's Vancouver, Canada facility and Best Theratronics Ltd. manufacturing facility in Ottawa, Canada.
  • This cyclotron is the first of multiple High Current Proton Cyclotrons that the TeamBest Global Companies will be shipping in the coming months of 2022.
  • For more information about TeamBest Global Companies and Best Cyclotron Systems, please visit:

Global Radiopharmaceuticals Market Trajectory & Analytics Research Report 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Vendredi, janvier 21, 2022
Pharmaceutical, Health, Oncology, Cardiology, CAGR, Electron, FDG, PET, COVID-19, Cardiology, Common beta emitters, Growth, PET/CT, Immunology, SPECT, Tissue, Cyclotron, Degenerative disease, Graphite-moderated reactor, Prognosis, Radionuclide, Drug development, Gamma camera, SPECT/CT, Cancer, Prevalence, Medical imaging, Pet, Radiopharmaceutical

The "Radiopharmaceuticals - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Radiopharmaceuticals - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Growth in the global market is supported by growing number of nuclear procedures driven by rise in prevalence of cancer, and heart diseases.
  • The market is further supported by the recent discovery of newer and successful therapeutic applications of radiopharmaceuticals in oncology and cardiology prognosis.
  • This segment currently accounts for a 24% share of the global Radiopharmaceuticals market.

TeamBest Global Companies Announce Merger of Best ABT Molecular Imaging & Best Cyclotron Systems

Retrieved on: 
Vendredi, janvier 7, 2022
General Health, Health, Other Manufacturing, Manufacturing, Proton, Carbon, Cyclotron, Radiation therapy, Marvell Software Solutions Israel, Molecular imaging, Marketing, News, TBG, Solution, Dijon, Phosphorus, Medical imaging, Online shopping, Brachytherapy

Two of the TeamBest Global Companies, Best ABT Molecular Imaging and Best Cyclotron Systems, have merged into one entity effective January 1, 2022 Best Cyclotron Systems, Inc.

Key Points: 
  • Two of the TeamBest Global Companies, Best ABT Molecular Imaging and Best Cyclotron Systems, have merged into one entity effective January 1, 2022 Best Cyclotron Systems, Inc.
    Its global headquarters are located in Springfield, Virginia, with manufacturing operations in Knoxville (TN) and Loves Park (IL) USA, Ottawa (ON) and Vancouver (BC) Canada, as well as Dijon, France.
  • Best Cyclotron Systems, Inc. manufactures a broad range of cyclotron systems with a worldwide team to provide sales, service, marketing, and customer support.
  • The newly merged entity has over 35 cyclotrons installed worldwide from 6 MeV High Current Proton to 70 MeV High Current Proton Cyclotrons.
  • Currently, there are 10 plus cyclotrons of various energies under manufacturing, including a 70 MeV High Current Proton Cyclotron.

DGAP-News: Eckert & Ziegler Receives Approval for Gallium-68 Generator for Brasil

Retrieved on: 
Lundi, novembre 22, 2021
Gesellschaft mit beschränkter Haftung, Prostate cancer, Prostate, Diagnosis, Radionuclide, News, Cancer, Cyclotron, DGAP, Breast, TecDAX, Deutsch, Wilms' tumor, Medicine, Gallium, ANVISA, ISIN, PET, Nuclear medicine, Infarction, Lists of diseases, Security (finance), Medical imaging

Eckert & Ziegler Radiopharma GmbH has received approval for its pharmaceutical 68Ge/68Ga generator GalliaPharm(R) from the Brazilian health authority ANVISA.

Key Points: 
  • Eckert & Ziegler Radiopharma GmbH has received approval for its pharmaceutical 68Ge/68Ga generator GalliaPharm(R) from the Brazilian health authority ANVISA.
  • GalliaPharm(R) is thus the first and currently the only pharmaceutical gallium generator approved in Brazil.
  • "The approval strengthens our market position in Brazil and marks another milestone in our expansion strategy", explains Dr. Lutz Helmke, Executive Director of Eckert & Ziegler AG and responsible for the Medical segment.
  • Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy.